Regardless of the continued strained financial local weather, we’ve seen some huge chunks of change thrown round in 2025.
Whereas early-stage funding stayed constrained for a lot of the yr, giant cheques concentrated round a smaller group of firms definitely prevailed. In some instances, twice.
These had been among the largest Australian startup raises of 2025, and the businesses that secured them. And in information that can shock nobody, there aren’t many ladies within the combine.
Firmus: $330 million and $500 million
September and November 2025
AI infrastructure startup Firmus raised $330 million in September because it accelerated plans for ‘Mission Southgate’, a nationwide community of AI information centres designed to help energy-intensive compute workloads.
If that weren’t sufficient, it went onto elevate one other cool $500 million just a few months later.
Initially based as a bitcoin mining enterprise, Firmus has repositioned itself round what it calls “inexperienced AI factories”, pitching sovereign AI infrastructure as each an financial and nationwide functionality concern.
Backed by Nvidia and information centre companions, the elevate positioned Firmus among the many largest beneficiaries of surging demand for AI compute in 2025.
Airwallex: $466 million and $498 million
Might and December 2025
Apparently, one elevate wasn’t sufficient for Airwallex, both. Again in Might, the Melbourne-founded fintech Airwallex raised a blockbuster $466 million Series F, pushing its valuation to $9.36 billion.
Simply six months later, it returned with $498 million in Series G, lifting that valuation to $12 billion and delivering the only largest mixed fundraising effort by an Australian startup in 2025.
Airwallex has spent the previous decade constructing international funds, banking, and treasury infrastructure for companies working throughout borders.
In 2025, it additionally signalled a shift towards embedding AI brokers straight into monetary operations, betting that autonomous finance will underpin its subsequent section of progress because it scales aggressively within the US forward of a possible IPO.
Synchron: $305 million
November 2025
Medtech startup Synchron secured $305 million in Series D in November, with $54 million supplied by the Nationwide Reconstruction Fund.
Initially spun out of the College of Melbourne, Synchron is growing a non-surgical mind implant that enables folks with paralysis to manage digital gadgets utilizing thought alone.
The funding will help the subsequent section of scientific trials and regulatory work as Synchron works towards industrial deployment of its Stentrode machine within the US.
Harrison.ai: $179 million
February 2025
The funding is getting used to scale its diagnostic platforms globally, together with Annalise.ai, which is now deployed throughout greater than 1,000 healthcare amenities in 15 international locations.
Harrison.ai’s expertise has reportedly demonstrated enhancements within the early detection of significant situations reminiscent of lung most cancers. The corporate was additionally on the centre of debates round how AI can broaden healthcare capability and the way affected person information must be ruled as these programs scale.
RayGen: $127 million (kind of)
April 2025
After a 12-month course of, RayGen completed its Series D in April. This introduced the overall elevate to $127 million after an initial $51 million tranche in 2024 and subsequent top-ups from strategic power traders and ARENA.
The Victorian startup develops next-generation photo voltaic and long-duration thermal storage expertise, with working tasks in Victoria and large-scale developments underway in South Australia and abroad. Its Carwarp facility can ship as much as 17 hours of steady energy to the grid.
Heidi Well being: $98 million
October 2025
Melbourne-based AI healthtech Heidi Well being raised $98 million in a Series B spherical in October, simply seven months after topping up its Collection A.
The elevate pushed Heidi’s valuation to $704 million and highlighted investor urge for food for healthcare instruments that deal with administrative burden at scale.
Heidi’s platform transcribes and processes clinician–affected person conversations into scientific notes and follow-up supplies, with utilization now spanning greater than 200 medical specialties throughout 116 international locations.
Morse Micro: $88 million
September 2025
Sydney deep tech firm Morse Micro raised $88 million in a Series C in September, together with $35 million from the federal authorities’s Nationwide Reconstruction Fund (NRF).
The corporate designs long-range, low-power Wi-Fi HaLow chips for IoT gadgets, with functions throughout agriculture, mining, power and sensible infrastructure.
The funding is getting used to speed up the commercialisation of the chips as international demand grows for low-power, long-range connectivity throughout industrial, agricultural and infrastructure functions.
Lorikeet: $54.4 million
August 2025
AI buyer help startup Lorikeet raised $54.4 million in a Series A in August, its third funding spherical in lower than 12 months.
The Sydney-founded startup builds AI ‘concierge brokers’ reportedly able to resolving complicated buyer points end-to-end throughout chat, e mail and voice.
Lorikeet’s prospects embrace Airwallex, Linktree and Eucalyptus, with the startup positioning its AI brokers as instruments that may resolve points end-to-end relatively than deflect prospects to self-serve workflows.
IND Expertise: $50 million
December 2025
Power expertise startup IND Expertise raised $50 million in December in its first institutional funding spherical.
Based after the Black Saturday bushfires, IND develops early fault detection programs that determine electrical failures earlier than they escalate into outages or fires.
IND is now targeted on scaling the deployment of its early fault detection expertise throughout utilities in Australia and abroad.
Vaxxas: $49.2 million
August 2025
Brisbane-based biotech Vaxxas raised $49.2 million in a Series D because it continues the event of its needle-free vaccine supply expertise, HD-MAP.
The elevate got here amid management modifications and workforce cuts, reflecting the more durable funding surroundings for biotech in 2025.
Vaxxas is now targeted on advancing HD-MAP by way of scientific trials whereas constructing out the manufacturing functionality required for industrial use.
- This story first appeared on SmartCompany. You possibly can read the original here.
